Overview

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Status:
Not yet recruiting

Trial end date:
2029-12-01

Target enrollment:

Participant gender:

Summary

This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Therapeutic Advances in Childhood Leukemia Consortium

Treatments:

Azacitidine
Cytarabine
Fludarabine
Trametinib